RDSMY has been the subject of a number of other research reports. JPMorgan Chase & Co. upgraded Koninklijke DSM from a “neutral” rating to an “overweight” rating in a report on Friday, July 5th. ABN Amro downgraded Koninklijke DSM from a “buy” rating to a “hold” rating in a report on Monday, August 5th. Finally, Zacks Investment Research upgraded Koninklijke DSM from a “sell” rating to a “hold” rating in a report on Saturday, August 17th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $30.00.
Shares of Koninklijke DSM stock traded up $0.32 during midday trading on Wednesday, reaching $29.57. 119,305 shares of the company’s stock traded hands, compared to its average volume of 111,982. The company has a market cap of $20.81 billion, a PE ratio of 17.09, a price-to-earnings-growth ratio of 3.60 and a beta of 1.39. The stock has a 50 day moving average of $30.34 and a 200-day moving average of $29.71. Koninklijke DSM has a 12 month low of $19.45 and a 12 month high of $32.25.
Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and materials businesses in the Netherlands, North America, the United Kingdom, France, Germany, Switzerland, the Asia-Pacific, and internationally.. The company operates through Nutrition, Materials, and Innovation Center segments.
Read More: What is net income?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.